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Abstract
Background Comorbidities increase the risk of coronavirus disease 2019 (COVID-19) hospitalization and mortality. As 
many comorbidities are common in patients with inflammatory bowel diseases (IBD), we sought to investigate the effects 
of comorbidities in these patients on infection severity.
Aim To evaluate association between individual comorbidities and COVID-19 infection severity among patients with IBD.
Methods Data were obtained from SECURE-IBD, an international registry created to evaluate COVID-19 outcomes in 
patients with IBD. We used multivariable regression to analyze associations between eleven non-IBD comorbidities and a 
composite primary outcome of COVID-19-related hospitalization or death. Comorbidities were first modeled individually, 
adjusting for potential confounders. Next, to determine the independent effect of comorbidities, we fit a model including all 
comorbidities as covariates.
Results We analyzed 2,035 patients from 58 countries (mean age 42.7 years, 50.6% male). A total of 538 patients (26.4%) 
experienced severe COVID-19. All comorbidities but a history of stroke and obesity were associated with severe infection 
in our initial analysis, with adjusted odds ratios ranging from 1.9 to 3.7. In a model including all comorbidities significantly 
associated with the composite outcome in the initial analysis, as well as other confounders, most comorbidities remained 
significant, with the highest risk in chronic kidney disease and chronic obstructive pulmonary disease.
Conclusion Many non-IBD comorbidities are associated with a two to threefold increased risk of COVID-19 hospitalization 
or death among patients with IBD. These data can be used to risk-stratify and guide treatment and lifestyle decisions during 
the ongoing pandemic.
Keywords Inflammatory bowel disease · Crohn’s disease · Ulcerative colitis · Coronavirus disease · Chronic kidney 
disease · Chronic obstructive pulmonary disease
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Introduction
Coronavirus disease 2019 (COVID-19) is a respiratory 
illness caused by the severe acute respiratory syndrome 
coronavirus 2 (SARS-CoV-2) virus. Although COVID-19 
infection generally presents as a mild or moderate illness, 
the infection can cause hospitalization, need for respir-
atory support, and death [1, 2]. Since its emergence in 
December 2019, COVID-19 has spread to over 200 differ-
ent countries, resulting in over 123 million infections and 
2.7 million deaths as of mid-March 2021[3]. Worldwide 
estimates for mortality due to COVID-19 are estimated 
to range from 0.01% to over 20%, depending on patient 
age [4, 5]. The severity of disease is also impacted by fac-
tors such as age, sex, and comorbidities [6]. In particular, 
the presence of hypertension, diabetes, chronic obstruc-
tive pulmonary disease (COPD), and cancer are important 
predictors of severe COVID-19 infection [7].
The effect of inflammatory bowel disease (IBD) and its 
treatments on the severity of COVID-19 infections is less 
understood. Two previous multicenter studies evaluated 
the risk of COVID-19 infection in patients with IBD, both 
finding the disease may present more severely in these 
patients when compared to the general population. These 
studies separately found hospitalization rates of patients 
with IBD who contracted COVID-19 to be close to 30%, 
much greater than seen in the general population [8, 9]. 
Patients with IBD may be predisposed to these more severe 
clinical outcomes compared to the larger, unaffected popu-
lation for a number of reasons. First, immune-mediated 
diseases such as IBD can be associated with ongoing sys-
temic inflammation and may predispose to thrombosis [10, 
11]. Both elevated C-reactive protein (CRP) and d-Dimer 
levels are predictors of the severity of COVID-19 infec-
tion, and as patients with IBD may start from an initial 
position of vulnerability, it is possible that COVID-19 
outcomes are worse in these patients [12, 13]. Second, 
the frequent use of immunosuppressant medications may 
also affect the clinical course of COVID-19 infection. It 
has previously been demonstrated that patients with IBD 
on immunosuppressant medication are at greater risk for 
morbidity from certain infectious processes, and this may 
be the case for COVID-19 as well [14]. Conversely, corti-
costeroid treatment and possibly other immunosuppressant 
therapy may provide a mortality benefit in severe COVID-
19 infection, likely by blunting the effects of the cytokine 
mediated surge [14–16]. Finally, patients with IBD have a 
significantly higher prevalence of comorbid medical con-
ditions, including respiratory disease, cardiovascular dis-
ease, and cancer compared to patients without IBD [17]. 
The presence of these comorbidities may place patients 
with IBD at risk for more severe COVID-19 infection, 
and indeed, existing multicenter research mentioned pre-
viously has demonstrated that a higher Charlson Comor-
bidity Index is associated with more severe COVID-19 
outcomes [8].
Our group has previously published research utilizing 
an international database of patients with IBD who were 
infected with COVID. A key finding was that, in patients 
with IBD, increasing age and number of comorbidities 
were significantly associated with the severity of COVID-
19 [18]. However, the relative effect of specific comorbidi-
ties in patients with IBD has not yet been established. We 
aimed to evaluate the impact of individual comorbidities 
on COVID-19 severity among patients with IBD. Based on 
prior research demonstrating associations between comor-
bidities and severe COVID-19 outcomes in the general pop-
ulation, as well as in patients with IBD, we hypothesized 
that most, if not all, comorbidities would be significantly 
associated with greater COVID-19 severity [6–8].
Methods
Data Source
This research utilized the Surveillance Epidemiology of Cor-
onavirus Under Research Exclusion for Inflammatory Bowel 
Disease (SECURE-IBD) database. The creation of this data-
base has been previously described [18]. In brief, healthcare 
providers reported demographic information of patients with 
IBD with confirmed COVID-19, as well as IBD treatments 
and outcomes of COVID-19 infection. Furthermore, report-
ers provided information regarding eleven comorbidities: 
asthma, cancer, cardiovascular disease, chronic liver disease, 
CKD, diabetes, a history of stroke, hypertension, obesity, 
COPD, and other chronic lung disease. Reporters were asked 
“Does the patient have any of the following comorbidities 
(check all that apply)?” and provided with a list of comor-
bidities to select from, as well as the opportunity to enter 
any other comorbidities afflicting the patient. Reporters are 
requested to submit cases after one week of symptoms and 
sufficient time has passed to observe the clinical course of 
the illness through resolution or death [18].
Quality Control
We identified potential duplicate records with matching 
age, sex, IBD disease type, country, and state (United States 
only), and reviewed these manually. Reports from nonvalid 
email addresses were flagged as potential errors and we per-
formed a Google search of reporters and practice locations 
to confirm legitimacy of reports.
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Statistical Analyses
This analysis utilized all reports to SECURE-IBD through 
November 8, 2020. Patient and disease characteristics 
were summarized by means and standard deviations for 
the continuous variables and by count and percentages for 
the categorical variables (Table 1). Our primary outcome 
was COVID-19 related hospitalization or death. We first 
analyzed associations between each individual comorbid-
ity and COVID-19 hospitalization or death using separate 
logistic regressions. Covariates included patient age and sex, 
as well as other variables that were significantly different 
between patients with and without the comorbidity in bivari-
ate analysis.
We next examined the independent effect of each comor-
bidity, adjusting for other comorbidities as well as patient 
age, patient sex, and IBD medication use, including 5-ami-
nosalicylates (ASA), biologic therapy (any tumor necrosis 
factor, IL-12/23, or integrin antagonist), and corticosteroids 
using logistic regression. Comorbidities found to not be sta-
tistically significant using separate logistic regression mod-
els were not incorporated into the final multivariable model.
All statistical analyses were carried out in R (R Core 
Team, 2019) and used the Tidyverse package [19, 20]. An 
alpha level < 0.05 was considered statistically significant for 
all comparisons.
Results
Data from 58 countries describing 2035 COVID-19 cases 
in patients with IBD were reported to the SECURE-IBD 
registry at the time of the study and included for analysis. 
The mean patient age was 42.7 years, 1030 (50.6%) patients 
were male, and 1139 (56.0%) had Crohn’s disease (CD). 
Among the 2035 patients, 538 (26.4%) experienced COVID-
19 hospitalization or death, and 64 (3.1%) died. The most 
common comorbidity was hypertension (12.6%), followed 
by cardiovascular disease (7.1%) and diabetes (5.8%). The 
study population is further summarized in Table 1.
In the first analysis, we performed separate logistic 
regressions for each comorbidity, adjusting for age, sex, 
and the other variables shown in Table 2. All examined 
comorbidities were statistically significant except for a his-
tory of stroke [adjusted odds ratio (aOR) 1.62, 95% confi-
dence interval (CI) 0.71–3.70] and obesity (aOR 1.07, 95% 
CI 0.80–1.43). Most comorbidities were associated with a 
two to threefold odds of hospitalization or death (Table 2). 
The highest aORs were observed for CKD (aOR 3.73, 95% 
CI 1.84–7.56) and COPD (aOR 3.55, 95% CI 1.66–7.58).
Next, we evaluated the independent effects of each comor-
bidity in a single model, adjusting for all other comorbidi-
ties, as patients with one comorbidity could be more likely 
Table 1  Baseline demographic and clinical characteristics of IBD 
patients with COVID-19 reported to the SECURE-IBD registry until 
August 2020
SECURE-IBD Surveillance Epidemiology of Coronavirus Under 
Research Exclusion for Inflammatory Bowel Disease, COVID-19 
coronavirus disease 2019, SD standard deviation, 5-ASA 5-aminosali-
cylic acid, IBD inflammatory bowel disease, COPD chronic obstruc-
tive pulmonary disease, BMI body mass index
a Unless otherwise specified, percentages do not include missing val-
ues or “unknown.” For all characteristics, less than 4% of data was 
missing and unknown, respectively, for each category. Percentages 
and n from each subcategory may not add up to the exact number of 




Total number of patients 2035
Age (mean, SD) 42.7 17.9











 Crohn’s disease 1139 56%
 Ulcerative colitis 854 42%
 IBD unspecified 42 2%




Janus kinase Inhibitors 25 1%
Other IBD treatment 67 3%
No IBD treatment 65 3%




Other chronic lung disease 34 2%
Hypertension 256 13%
Cancer 43 2%
History of stroke 29 1%
Chronic kidney disease 48 2%
Chronic liver disease 69 3%
Obesity (BMI ≥ 30) 335 16%
Cigarette smoker 84 4%
Other tobacco user 16 1%
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to have others (Table 3). As previously observed, increased 
patient age (aOR 1.03, 95% CI 1.02–1.04) and use of corti-
costeroids (aOR 2.90, 95% CI 2.09–4.03) were associated 
with higher odds of hospitalization or death. Associations 
with male sex (aOR 1.22, 95% CI 0.97–1.53) and use of 
5-ASA (aOR 1.13, 95% CI 0.88–1.45) were not statistically 
significant. The use of biologic therapy was observed to 
have a protective association (aOR 0.51, 95% CI 0.40–0.65). 
Overall, the effect size for most comorbidities was similar in 
this fully adjusted analysis compared to individual analysis 
of each comorbidity. CKD (aOR 3.02, 95% CI 1.45–6.31) 
and COPD (aOR 2.92, 95% CI 1.32–6.48) remained the most 
detrimental comorbidities. However, the odds of association 
of adverse COVID-19 outcomes with cancer (aOR 1.87, 95% 
CI 0.94–3.75) and cardiovascular disease (aOR 1.34, 95% 
CI 0.87–2.06) were attenuated and no longer statistically 
significant in the fully adjusted model. Directions and mag-
nitudes of all effects were similar when the outcome variable 
was a need for mechanical ventilation or patient death.
Discussion
We used an international dataset of over 2000 reports of 
COVID-19 infection in patients with IBD to understand the 
relative effects of comorbidities on the severity of COVID-
19. Consistent with literature in the general population, we 
observed that most non-IBD comorbidities are associated 
with a two to threefold risk of hospitalization or death. 
Given the high comorbidity burden for patients with IBD, 
these findings represent an important factor in risk-stratify-
ing patients during the course of this pandemic and may be 
used to inform clinical care discussions as well as lifestyle 
decisions regarding returning to work, school, and other nor-
mal activities.
This study builds upon prior work indicating that, among 
patients with IBD, the presence of comorbidities is a risk 
factor for more severe COVID-19. Bezzio et al. found a 
strong association between Charlson Comorbidity Index 
and death among patients with IBD affected by COVID-19 
(OR 16.66, 95% CI 1.80–153.9), research by Singh et al. 
Table 2  Association of non-IBD comorbidities and adverse COVID-
19 outcomes (hospitalization and death) in IBD patients with 
COVID-19 in the SECURE-IBD registry in separate models
SECURE-IBD Surveillance Epidemiology of Coronavirus Under 
Research Exclusion for Inflammatory Bowel Disease, COVID-19 cor-
onavirus disease 2019, COPD chronic obstructive pulmonary disease, 
aOR adjusted odds ratio, CI confidence interval
a Each comorbidity was tested in a separate model after adjusting for 
variables other than comorbidities that were significantly associated 
with the outcome on bivariate analyses
b Adjusted for age, sex, race, and ethnicity
c Adjusted for age, sex, race, biologic therapy, 5-ASA, immunomodu-
lators, and cigarette use
d Adjusted for age, sex, biologic therapy, 5-ASA, corticosteroids, and 
cigarette use
e Adjusted for age and sex
f Adjusted for age, sex, race, biologic therapy, and corticosteroids
g Adjusted for age, sex, biologic therapy, 5-ASA, and corticosteroids
h Adjusted for age, sex, race, ethnicity, biologic therapy, and 5-ASA
i Adjusted for age, sex, race, biologic therapy, and cigarette use
j Adjusted for age, sex, race, biologic therapy, 5-ASA, and cigarette 
use
k Adjusted for age, sex, biologic therapy, 5-ASA, and corticosteroids
l Adjusted for age, sex, race, biologic therapy, 5-ASA, corticosteroids, 
and cigarette use
Comorbidity aOR (95% CI)a P value
Asthmab 1.88 (1.21–2.92) 0.005
Cancerc 1.96 (1.01–3.81) 0.047
Cardiovascular  diseased 1.86 (1.25–2.78) 0.002
Chronic liver  diseasee 2.33 (1.39–3.89) 0.001
Chronic kidney  diseasef 3.73 (1.84–7.56) < 0.001
COPDg 3.55 (1.66–7.58) 0.001
Diabetesh 2.73 (1.79–4.18) < 0.001
History of  strokei 1.62 (0.71–3.70) 0.249
Hypertensionj 2.01 (1.48–2.73) < 0.001
Obesityk 1.07 (0.80–1.43) 0.635
Other chronic lung  diseasel 3.02 (1.39–6.55) 0.005
Table 3  Association of non-IBD comorbidities and adverse COVID-
19 outcomes (hospitalization and death) in IBD patients with 
COVID-19 in the SECURE-IBD registry in a composite model
SECURE-IBD Surveillance Epidemiology of Coronavirus Under 
Research Exclusion for Inflammatory Bowel Disease, COVID-19 cor-
onavirus disease 2019, COPD chronic obstructive pulmonary disease, 
5-ASA 5-aminosalicylic acid, aOR adjusted odds ratio, CI confidence 
interval
a These variables were incorporated into a multivariable logistic 
regression, with hospitalization or death as the response variable
Variablea aOR (95% CI) P value
Asthma 1.96 (1.24–3.11) 0.004
Diabetes 1.95 (1.22–3.11) 0.005
Cancer 1.87 (0.94–3.75) 0.076
Cardiovascular disease 1.34 (0.87–2.06) 0.186
Chronic liver disease 1.97 (1.14–3.39) 0.015
Chronic kidney disease 3.02 (1.45–6.31) 0.003
COPD 2.92 (1.32–6.48) 0.008
Hypertension 1.50 (1.07–2.10) 0.018
Other chronic lung disease 2.38 (1.06–5.35) 0.035
Age 1.03 (1.02–1.04) < 0.001
Male sex 1.22 (0.97–1.53) 0.083
5-ASA 1.13 (0.88–1.45) 0.343
Corticosteroids 2.90 (2.09–4.03) < 0.001
Biologic therapy 0.51 (0.40–0.65) < 0.001
Digestive Diseases and Sciences 
1 3
indicated that patients with IBD that experienced severe 
COVID-19 had a greater presence of comorbidities (P < 0.05 
for essential hypertension, diabetes mellitus, ischemic heart 
diseases, heart failure, cerebrovascular diseases, and chronic 
kidney disease), and prior work from our group indicated 
that the presence of at least two non-IBD comorbidities was 
positively associated with the risk of intensive care hospi-
talization and/or death (aOR 2.9, 95% CI 1.1–7.8) [8, 18, 
21]. Our analyses similarly demonstrated that most comor-
bidities were associated with worse COVID-19 outcomes. 
Furthermore, each statistically significant comorbidity had 
an odds ratio greater than 1.8, indicating that the resulting 
increase in the odds of hospitalization or death is relatively 
high. CKD and COPD conferred the greatest risk, both with 
odds ratios greater than 3.5. After a second analysis adjust-
ing for the independent effects of each comorbidity, CKD 
and COPD remained the most detrimental comorbidities. 
The associations of these two comorbidities with severity of 
COVID-19 infection are consistent with prior research. Stud-
ies conducted within the general population that examined 
the effects of both CKD and COPD showed both comorbidi-
ties to confer greatly increased risk of severe infection. Thus, 
our findings in the IBD population are consistent with this 
prior literature [22, 23]. A history of stroke was not statisti-
cally significant. This result is surprising, as prior research 
suggested that this comorbidity is a significant predictor of 
severe COVID-19 infection among the general population 
[24]. This may be attributable to the fact that stroke patients 
are often placed on oral anticoagulants, which may have a 
protective effect in the prothrombotic milieu of COVID-19 
infection [25]. Furthermore, obesity was not statistically sig-
nificant. This, too, is in contrast to other research suggesting 
that obesity is a strongly detrimental factor in COVID-19 
infection in the general population [26]. However, this prior 
study did not account for the same comorbidities as did this 
research, and it is possible that the observed effect of obesity 
was mediated by other comorbid conditions.
As with prior analyses of data from SECURE-IBD, we 
found that steroid use was associated with adverse COVID-
19 outcomes while biologic use was protective [18]. In con-
trast to prior work, associations between 5-ASA/mesalamine 
and COVID-19 hospitalization or death were not significant, 
perhaps owing to tighter control of confounding by non-
IBD comorbidities in this larger analysis with more granular 
assessment of individual comorbidities.
This study’s strength stems largely from the SECURE-
IBD database, a large international registry created through 
the collaborative effort of healthcare providers across the 
world which allowed us to analyze over 2,000 COVID-19 
infections in patients with IBD. Nevertheless, IBD provid-
ers may not have fully reported the presence of comorbidi-
ties, leading to misclassification of exposure that may have 
slightly attenuated observed associations. Another limitation 
is the potential for reporting bias. Data came from a conveni-
ence sample, which seems to over-represent white patients 
from the United States. Furthermore, the dataset might also 
over-represent severe infection. It may be that a doctor is 
more likely to be aware of or report a COVID-19 infection 
that presents more severe symptoms than one that does not. 
Further, it was unexpected that cancer was not significantly 
linked with severe infection in the independent effects 
analysis, as it has previously shown association with severe 
infection in the general population [7]. Perhaps this discrep-
ancy was due to the lack of granularity with regards to can-
cer type, stage, treatment, and other clinical details in the 
SECURE IBD database which may have diluted the effect 
of active cancer, including metastatic cancer or cancers cur-
rently treated with chemotherapy. Lastly, it is important to 
acknowledge that this analysis is observational, and the cor-
relation described throughout this research does not neces-
sarily imply causation due to the possibility of unmeasured 
confounding and/or pure chance.
As COVID-19 continues to sweep through our society as 
we approach a new normal, it is important for patients and 
doctors to be able to stratify and assess risk, especially for 
patients with IBD who may already be predisposed to worse 
clinical outcomes. As expected, we found patient age and 
corticosteroid use linked with more severe COVID-19, as 
were many of the comorbidities we analyzed. In particular, 
CKD and COPD greatly increased risk of severe infection. 
These findings can be used to help patients and their pro-
viders make informed decisions about returning to normal 
activities and the level of precautions that should be taken.
Conclusion
Many comorbidities are associated with severe COVID-
19 infection among patients with IBD. CKD and COPD 
were the most detrimental of all comorbidities in the study, 
both conferring approximately a threefold-increased risk of 
severe infection.
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